Search

As of 2022, the prevalence of Alzheimer’s disease (AD) among individuals aged 65 and older is estimated to be 6.2 million in the United States. This figure is predicted to grow to 13.8 million by 2060. An accurate assessment of neuropathologic changes represents a critical step in understanding the underlying mechanisms in AD. The current method for assessing postmortem Alzheimer’s disease neuropathologic change follows version 11 of the National Alzheimer’s Coordinating Center (NACC) coding guidebook. Ambiguity regarding steps in the ABC scoring method can lead to increased time or inaccuracy in staging AD. We present a concise overview of how this postmortem diagnosis is made and relate it to the evolving understanding of antemortem AD biomarkers.

Background: Hyperglycemic-hemichorea is a well-established clinical entity which leads to signal changes on brain MRI. We are reporting a case of hyperglycemic-hemichorea where the DaT scan showed reduced uptake bilaterally. Case Report: A 57-year-old female was seen in the clinic for hemichorea due to hyperglycemia. Her brain magnetic resonance imaging (MRI) showed increased T1 signal intensity in bilateral lenticular nuclei and the DaT scan showed reduced uptake on both sides. Discussion: This case highlights the importance of performing a DaT scan in the correct clinical context, as an abnormality on brain MRI can lead to false-positive DaT scan results.